- Home
- WYY vs ATNM Comparison
WYY vs ATNM Comparison
Compare WYY & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WYY
- ATNM
- Stock Information
- Founded
- WYY 1991
- ATNM 2000
- Country
- WYY United States
- ATNM United States
- Employees
- WYY N/A
- ATNM N/A
- Industry
- WYY EDP Services
- ATNM Biotechnology: Pharmaceutical Preparations
- Sector
- WYY Technology
- ATNM Health Care
- Exchange
- WYY Nasdaq
- ATNM Nasdaq
- Market Cap
- WYY 48.9M
- ATNM 50.2M
- IPO Year
- WYY 1998
- ATNM N/A
- Fundamental
- Price
- WYY $6.80
- ATNM $1.27
- Analyst Decision
- WYY Strong Buy
- ATNM Strong Buy
- Analyst Count
- WYY 3
- ATNM 2
- Target Price
- WYY $8.67
- ATNM $4.50
- AVG Volume (30 Days)
- WYY 74.1K
- ATNM 295.8K
- Earning Date
- WYY 11-13-2025
- ATNM 11-14-2025
- Dividend Yield
- WYY N/A
- ATNM N/A
- EPS Growth
- WYY N/A
- ATNM N/A
- EPS
- WYY N/A
- ATNM N/A
- Revenue
- WYY $144,421,640.00
- ATNM N/A
- Revenue This Year
- WYY $9.07
- ATNM N/A
- Revenue Next Year
- WYY $13.20
- ATNM N/A
- P/E Ratio
- WYY N/A
- ATNM N/A
- Revenue Growth
- WYY 16.25
- ATNM N/A
- 52 Week Low
- WYY $2.19
- ATNM $1.03
- 52 Week High
- WYY $7.55
- ATNM $2.41
- Technical
- Relative Strength Index (RSI)
- WYY 59.68
- ATNM 33.84
- Support Level
- WYY $6.33
- ATNM $1.39
- Resistance Level
- WYY $7.19
- ATNM $1.40
- Average True Range (ATR)
- WYY 0.53
- ATNM 0.09
- MACD
- WYY -0.01
- ATNM -0.02
- Stochastic Oscillator
- WYY 59.89
- ATNM 6.86
About WYY WidePoint Corporation
WidePoint Corp is a provider of Technology Management as a Service (TMaaS) that consists of federally certified communications management, identity management, interactive bill presentment and analytics, and an Information Technology as a Service solution. Its solutions include Telecom Lifecycle Management, Digital billing communications solutions, and Mobile and Identity management. Geographically, the company generates a majority of its revenue from the United States and the rest from Europe.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.